What is Lila Sciences?
Headquartered in Cambridge, Massachusetts, Lila Sciences is a venture-backed enterprise focused on the development of scientific superintelligence. Founded in 2023, the company leverages its AI Science Factory (AISF) to conduct autonomous experiments at a scale that transcends human limitations. The platform has already demonstrated significant utility in the discovery of novel antibodies, green hydrogen catalysts, and advanced carbon capture materials. Under the leadership of CEO Geoffrey von Maltzahn and Chief Scientist George Church, the company is positioning itself as a critical infrastructure provider for the future of the bioeconomy and materials science sectors.
How much funding has Lila Sciences raised?
Lila Sciences has raised a total of $435M across 2 funding rounds:
Angel/Seed
$200M
Series A
$235M
Angel/Seed (2025): $200M with participation from Modi Ventures, General Catalyst, Blue Horizon Advisors, Ark Venture Fund, Flagship Pioneering, March Capital, and Altitude Life Science Ventures
Series A (2025): $235M led by Collective Global and Braidwell
Key Investors in Lila Sciences
Collective Global
An aligned investment collective that partners with elite venture managers to provide strategic capital solutions for growth-stage companies.
Braidwell
A firm dedicated to transforming human health by providing flexible capital and deep partnership to companies across all stages of the capital structure.
General Catalyst
A prominent venture capital firm that supports transformational business opportunities by deploying strategic capital and operational expertise to build enduring enterprises.
What's next for Lila Sciences?
With the recent capital infusion, Lila Sciences is well-positioned to execute its planned expansion into key global innovation hubs, including San Francisco and London. The strategic roadmap focuses on enhancing the autonomous capabilities of the AI Science Factory to tackle increasingly complex challenges in genetic medicine and industrial chemistry. As the company scales, it will likely prioritize the commercialization of its discovery pipeline, moving from experimental validation to high-impact industrial applications. Investors are closely watching how the firm will leverage its unique combination of CRISPR-pioneering expertise and generative AI to redefine the economics of scientific research and development.
See full Lila Sciences company page
